Related Experiment Videos
Serological evaluation of a measles, mumps, and rubella vaccine
C M Robertson1, V J Bennett, N Jefferson
1Department of Community Medicine, Oxfordshire Health Authority, Headington.
Insights
The new combined measles, mumps, and rubella vaccine shows high effectiveness and safety in British children. This study supports its introduction into routine immunization programs.
Area of Science:
- Pediatrics
- Immunology
- Public Health
Background:
- The routine immunization program in Britain is set to include a combined measles, mumps, and rubella (MMR) vaccine.
- Assessing the efficacy and safety of this new combined vaccine is crucial for its successful implementation.
Purpose of the Study:
- To evaluate the antibody response and clinical reactions of a new combined measles, mumps, and rubella vaccine.
- To compare the new combined vaccine against a single-component measles vaccine in children aged 13 months.
Main Methods:
- A controlled study involving 319 children aged 13 months.
- Comparison of seroconversion rates and clinical reactions between the combined MMR vaccine and a single measles vaccine.
Main Results:
- The combined vaccine achieved high seroconversion rates: 93% for measles, 99% for rubella, and 100% for mumps.
- The single measles vaccine showed 92% seroconversion for measles, with no response for rubella or mumps.
- No increase in clinical reactions was observed with the combined MMR vaccine compared to the single measles vaccine.
Conclusions:
- The combined measles, mumps, and rubella vaccine demonstrates significant efficacy and a favorable safety profile in a British pediatric population.
- These findings provide strong evidence supporting the introduction of the combined MMR vaccine into Britain's routine immunization schedule.
Abstract:
Combined measles, mumps, and rubella vaccination is soon to become available in Britain in the routine immunisation programme. A controlled study was performed in 319 children, aged 13 months, to assess the antibody response and clinical reactions to a new combined measles, mumps, and rubella vaccine in comparison with a single component measles vaccine. In the children who received the combined vaccine, seroconversion was established in 93% for measles, 99% for rubella, and 100% for mumps. In the children who received the single measles vaccine, seroconversion was established in 92% for measles and in none for rubella and mumps. There was no increase in clinical reactions after the measles, mumps, and rubella vaccine compared with the measles vaccine. These results suggest that this combined vaccine would be effective and safe in a British population and give further support for the introduction of the combined measles, mumps, and rubella vaccine to Britain.